(NASDAQ: VTVT) Vtv Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.21%.
Vtv Therapeutics's earnings in 2026 is $2,252,000.On average, 7 Wall Street analysts forecast VTVT's earnings for 2026 to be -$9,465,559, with the lowest VTVT earnings forecast at -$21,500,852, and the highest VTVT earnings forecast at $82,717. On average, 7 Wall Street analysts forecast VTVT's earnings for 2027 to be -$17,292,143, with the lowest VTVT earnings forecast at -$30,147,515, and the highest VTVT earnings forecast at -$10,298,241.
In 2028, VTVT is forecast to generate -$19,455,778 in earnings, with the lowest earnings forecast at -$32,733,793 and the highest earnings forecast at -$12,531,594.